Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design

Sally Worsley, Neil Snowise, David M.G. Halpin, Dawn Midwinter, Afisi S. Ismaila, Elaine Irving, Leah Sansbury, Maggie Tabberer, David Leather, Chris Compton

Source: ERJ Open Res, 5 (4) 00061-2019; 10.1183/23120541.00061-2019
Journal Issue: October
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Sally Worsley, Neil Snowise, David M.G. Halpin, Dawn Midwinter, Afisi S. Ismaila, Elaine Irving, Leah Sansbury, Maggie Tabberer, David Leather, Chris Compton. Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design. ERJ Open Res, 5 (4) 00061-2019; 10.1183/23120541.00061-2019

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013

Long-term safety data with once-daily budesonide in mild asthma: results from the START study
Source: Eur Respir J 2003; 22: Suppl. 45, 34s
Year: 2003

Health care resource utilization following addition of montelukast or salmeterol to fluticasone in patients with inadequately controlled asthma (IMPACT trial)
Source: Eur Respir J 2004; 24: Suppl. 48, 127s
Year: 2004

Real-world study to evaluate the safety and effectiveness of fluticasone propionate/formoterol (FP/FORM) in patients with asthma
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017


Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients
Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Year: 2018




Safety of formoterol in asthma clinical trials: an update
Source: Eur Respir J 2014; 43: 103-114
Year: 2004



The cost-effectiveness of early intervention with inhaled budesonide once daily: an international comparison of the results from the START study
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data
Source: Eur Respir J 2007; 30: Suppl. 51, 612s
Year: 2007

Efficacy of the using budesonide/formoterol in patients with bronchial asthma (BA): the study of routine clinical practice
Source: Eur Respir J 2006; 28: Suppl. 50, 499s
Year: 2006

Assessment of the bioequivalence of two DPIs containing fluticasone and salmeterol, in patients with controlled or partly controlled asthma
Source: International Congress 2016 – Clinical characteristics of asthma
Year: 2016


A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone
Source: Eur Respir J 2003; 22: Suppl. 45, 287s
Year: 2003

Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice: a randomised real-life study
Source: Eur Respir J 2006; 28: Suppl. 50, 613s
Year: 2006

Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014

INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020


A single-dose double-blind study comparing efficacy of two dry powder inhalers containing budesonide and formoterol in asthmatic patients
Source: International Congress 2016 – Asthma management
Year: 2016


A post-marketing study to evaluate the safety and tolerability of a non-chlorofluorocarbon salbutamol inhaler in asthmatic patients in general practice
Source: Eur Respir J 2002; 20: Suppl. 38, 78s
Year: 2002

Pooled analysis of the efficacy and safety from two non-interventional studies of fluticasone propionate/formoterol pMDI
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

Clinical phenotypes of asthmatics who require long-term use of tiotropium for asthma control: a real-world study
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019